At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the AP. Source
No articles found.
Galectin Therapeutics is a biotechnology company focused on discovery and developm...
Galectin Therapeutics is a biotechnology compan...
Medivie Therapeutic is an Israeli public company, which developed Laboraide – a br...
Medivie Therapeutic is an Israeli public compan...
OptimizeRx® (OPRX) provides unique physician and consumer platforms and strategies...
OptimizeRx® (OPRX) provides unique physician an...
United-Guardian, Inc. ("United") is a diversified company that conducts research, ...
United-Guardian, Inc. ("United") is a diversifi...
Join the National Investor Network and get the latest information with your interests in mind.